Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose Escalation and Expansion Study of Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Patients With Newly Diagnosed or Relapsed/Refractory Multiple Myeloma

NCT05259839 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT05259839
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05259839 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose Escalation and Expansion Study of Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Patients With Newly Diagnosed or Relapsed/Refractory Multiple Myeloma
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Active, not recruiting
Start date
October 20, 2022
Completion date
September 30, 2033
Enrollment
283 (actual)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory multiple myeloma